Search results for " insulin"

showing 10 items of 237 documents

Reduced circulating sTWEAK levels are associated with metabolic syndrome in elderly individuals at high cardiovascular risk

2014

BACKGROUND: The circulating soluble TNF-like weak inducer of apoptosis (sTWEAK) is a cytokine that modulates inflammatory and atherogenic reactions related to cardiometabolic risk. We investigated the association between sTWEAK levels and metabolic syndrome (MetS) and its components in older subjects at high cardiovascular risk. METHODS: Cross-sectional analysis of 452 non-diabetic individuals (men and women aged 55-80 years) at high cardiovascular risk. MetS was defined by AHA/NHLBI and IDF criteria. Logistic regression analyses were used to estimate odds ratios (ORs) for MetS and its components by tertiles of serum sTWEAK concentrations measured by ELISA. RESULTS: sTWEAK concentrations we…

MaleSíndrome metabòlicamedicine.medical_specialtyEpidemiologyRisk factors in diseasesCross-sectional studyEndocrinology Diabetes and MetabolismRenal functionInsulin resistanceRisk FactorsInternal medicineDiabetes mellitusmedicineHumansEpidemiologiasTWEAKAbdominal obesityOriginal InvestigationAgedAged 80 and overMetabolic SyndromeMalalties cardiovascularsFactors de risc en les malaltiesbusiness.industryBiochemical markersHypertriglyceridemiaCytokine TWEAKInsulin resistanceOdds ratioMiddle AgedCardiovascular riskmedicine.diseaseMetabolic syndromeCross-Sectional StudiesCardiovascular diseasesCardiovascular DiseasesTumor Necrosis FactorsMarcadors bioquímicsFemaleResistència a la insulinamedicine.symptomMetabolic syndromeCardiology and Cardiovascular MedicinebusinessBiomarkersCardiovascular Diabetology
researchProduct

Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosis

2003

Familial hypobetalipoproteinemia (FHBL) subjects may develop fatty liver. Liver fat was assessed in 21 FHBL with six different apolipoprotein B (apoB) truncations (apoB-4 to apoB-89) and 14 controls by magnetic resonance spectroscopy (MRS). Liver fat percentages were 16.7 +/- 11.5 and 3.3 +/- 2.9 (mean +/- SD) (P = 0.001). Liver fat percentage was positively correlated with body mass index, waist circumference, and areas under the insulin curves of 2 h glucose tolerance tests, suggesting that obesity may affect the severity of liver fat accumulation in both groups. Despite 5-fold differences in liver fat percentage, mean values for obesity and insulin indexes were similar. Thus, for similar…

MaleVery low-density lipoproteinSettore MED/09 - Medicina InternaApolipoprotein Bmedicine.medical_treatmentPalmitic AcidLipoproteins VLDLSeverity of Illness IndexTriglyceridevery low density lipoprotein assemblyBiochemistryBody Mass IndexMagnetic resonence spectroscopy; Nonalcoholic fatty liver; Nonesterified fatty acids; Very low density lipoprotein assembly; Adult; Body Mass Index; Dietary Fats; Fatty Liver; Female; Glucose Tolerance Test; Humans; Hypobetalipoproteinemias; Insulin Resistance; Lipoproteins VLDL; Liver Diseases; Male; Middle Aged; Obesity; Palmitic Acids; Severity of Illness Index; Triglycerides; EndocrinologyHypobetalipoproteinemiaschemistry.chemical_compoundEndocrinologyDietary FatGlucose tolerance testmedicine.diagnostic_testbiologyChemistryLiver DiseasesLiver DiseaseFatty liverMiddle AgedFemalemagnetic resonence spectroscopyHumanAdultmedicine.medical_specialtyPalmitic Acidsnonesterified fatty acidsQD415-436Internal medicinemedicinenonalcoholic fatty liverHumansObesityTriglyceridesTriglycerideInsulinNonesterified fatty acidCell BiologyGlucose Tolerance Testmedicine.diseaseDietary FatsFatty LiverEndocrinologybiology.proteinHypobetalipoproteinemiaInsulin ResistanceSteatosisHypobetalipoproteinemiaJournal of Lipid Research
researchProduct

Metformin: Sex/Gender Differences in Its Uses and Effects-Narrative Review

2022

Metformin (MTF) occupies a major and fundamental position in the therapeutic management of type 2 diabetes mellitus (T2DM). Gender differences in some effects and actions of MTF have been reported. Women are usually prescribed lower MTF doses compared to men and report more gastrointestinal side effects. The incidence of cardiovascular events in women on MTF has been found to be lower to that of men on MTF. Despite some promising results with MTF regarding pregnancy rates in women with PCOS, the management of gestational diabetes, cancer prevention or adjunctive cancer treatment and COVID-19, most robust meta-analyses have yet to confirm such beneficial effects.

Maleendocrine system diseasesGeneral MedicineMetformin gender insulin resistanceMetforminCOVID-19 Drug TreatmentSex FactorsDiabetes Mellitus Type 2Pregnancygender ; insulin resistance ; metforminHumansHypoglycemic AgentsFemalePolycystic Ovary Syndrome
researchProduct

Diabetic Goto Kakizaki rats as well as type 2 diabetic patients show a decreased diurnal serum melatonin level and an increased pancreatic melatonin-…

2006

There are functional inter-relationships between the beta cells of the endocrine pancreas and the pineal gland, where the synchronizing circadian molecule melatonin originates. The aim of this study was to elucidate a putative interaction between insulin and melatonin in diabetic patients and a diabetic rat model. We analyzed glucose, insulin, and melatonin levels of type 2 patients, as well as type 2 diabetic Goto Kakizaki (GK) rats by radioimmunoassay. Expression of pancreatic melatonin and pineal insulin receptors, as well as arylalkylamine-N-acetyltransferase (AANAT), was determined by real-time reverse transcriptase polymerase chain reaction (RT-PCR). The AANAT enzyme activity was meas…

Maleendocrine systemmedicine.medical_specialtyAANATmedicine.medical_treatmentReceptors MelatoninBiologyArylalkylamine N-AcetyltransferasePineal GlandMelatonin receptorMelatoninPineal glandEndocrinologyInternal medicinemedicineAnimalsHumansInsulinRats WistarPancreasMelatoninPancreatic isletsInsulinReceptor InsulinCircadian RhythmRatsmedicine.anatomical_structureEndocrinologyDiabetes Mellitus Type 2Beta cellhormones hormone substitutes and hormone antagonistsEndocrine glandmedicine.drugJournal of Pineal Research
researchProduct

Hydrolyzed infant formula and early β-cell autoimmunity: a randomized clinical trial.

2014

Importance The disease process leading to clinical type 1 diabetes often starts during the first years of life. Early exposure to complex dietary proteins may increase the risk of β-cell autoimmunity in children at genetic risk for type 1 diabetes. Extensively hydrolyzed formulas do not contain intact proteins. Objective To test the hypothesis that weaning to an extensively hydrolyzed formula decreases the cumulative incidence of diabetes-associated autoantibodies in young children. Design, Setting, and Participants A double-blind randomized clinical trial of 2159 infants with HLA-conferred disease susceptibility and a first-degree relative with type 1 diabetes recruited from May 2002 to Ja…

Maleinsulin-Secreting CellsautoantibodiesAutoimmunity2700 General MedicineGastroenterologylaw.invention0302 clinical medicineRandomized controlled trialnewbornlawCaseindouble-blind methodCumulative incidence030212 general & internal medicinehumans: Multidisciplinary general & others [D99] [Human health sciences]childHazard ratioGeneral Medicinefollow-up studiesInfant Formulaanimalscaseinstype 1femaleMilkbreast feedinghydrolysisdiabetes mellitusRiskmedicine.medical_specialty: Multidisciplinaire généralités & autres [D99] [Sciences de la santé humaine]β-cell autoimmunity610 Medicine & health030209 endocrinology & metabolismWeaningArticlehydrolyzed infant formula03 medical and health sciencesInternal medicineDiabetes mellitusHydrolyzed infant formula and early β-cell autoimmunitymedicineanimals; autoantibodies; breast feeding; caseins; child; diabetes mellitus; type 1; dietary proteins; double-blind method; female; follow-up studies; humans; hydrolysis; incidence; infant; newborn; insulin-Secreting Cells; Male; Milk; Risk; Weaning; Autoimmunity; Infant FormulaType 1 diabetesbusiness.industrydietary proteinsta1183Infant Newbornmedicine.diseaseta3123infantDiabetes Mellitus Type 1EndocrinologyInfant formula10036 Medical ClinicincidencebusinessBreast feeding
researchProduct

Combined therapy with insulin and growth hormone in 17 patients with type-1 diabetes and growth disorders.

2013

<b><i>Background/Aim:</i></b> Combined growth hormone (GH) and insulin therapy is rarely prescribed by pediatric endocrinologists. We investigated the attitude of Italian physicians to prescribing that therapy in the case of short stature and type-1 diabetes (T1DM). <b><i>Methods:</i></b> A questionnaire was sent and if a patient was identified, data on growth and diabetes management were collected. <b><i>Results:</i></b> Data from 42 centers (84%) were obtained. Of these, 29 centers reported that the use of combined therapy was usually avoided. A total of 17 patients were treated in 13 centers (GH was started before T1…

Malemedicine.medical_specialtyAdolescentGrowth hormone; Insulin therapy; GH deficiency; Type-1 diabetes; Turner syndromeTurner syndromeEndocrinology Diabetes and Metabolismmedicine.medical_treatmentType-1 diabeteseducationDwarfismTYPE I (INSULIN-DEPENDENT) DIABETES MELLITUSGrowth hormoneSettore MED/38 - Pediatria Generale E SpecialisticaEndocrinologyInsulin resistancePharmacotherapySurveys and QuestionnairesInternal medicineDiabetes mellitusgrowth hormone treatment; TYPE I (INSULIN-DEPENDENT) DIABETES MELLITUSTurner syndromemedicineHumansHypoglycemic AgentsInsulinChildDwarfism PituitaryGrowth hormoneGrowth DisordersGH deficiencyType 1 diabetesHuman Growth Hormonebusiness.industryInsulingrowth hormone treatmentmedicine.diseaseDiabetes Mellitus Type 1EndocrinologyChild PreschoolPediatrics Perinatology and Child HealthInsulin therapyDrug Therapy CombinationFemaleInsulin Resistancebusiness
researchProduct

Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial β-cell protection in individuals with type 2 diabetes

2010

AIM Postprandial release of intact proinsulin (IP) is an independent marker for beta-cell dysfunction in patients with type 2 diabetes. This open-label, parallel-group, two-arm, pilot study compared the beta-cell protective effect of adding insulin glargine (GLA) vs. NPH insulin to ongoing metformin. MATERIAL AND METHODS Overall, 28 insulin-naive type 2 diabetes subjects (mean +/- SD age, 61.5 +/- 6.7 years; diabetes duration, 9.8 +/- 6.5 years; HbA1c, 7.1 +/- 0.5%; BMI, 30.7 +/- 4.3 kg/m(2)) treated with metformin and sulfonylurea were randomized to add once-daily GLA or NPH at bedtime. At baseline and after 3 months, subjects received a standardized breakfast, lunch and dinner, with pre- …

Malemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentInsulin IsophaneInsulin GlarginePilot ProjectsNPH insulinType 2 diabetesNPH insulinDrug Administration ScheduleEndocrinologyInsulin-Secreting CellsInternal medicineDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic AgentsInsulinintact proinsulinGlycated Hemoglobinbusiness.industryInsulin glargineInsulindigestive oral and skin physiologynutritional and metabolic diseasesFastingOriginal ArticlesMiddle AgedPostprandial Periodmedicine.diseaseMetforminMetforminInsulin Long-ActingEndocrinologyPostprandialDiabetes Mellitus Type 2beta cell stressDrug Therapy CombinationFemalebusinessmedicine.drugBlood samplingDiabetes, Obesity and Metabolism
researchProduct

Impact of insulin resistance on cardiac and vascular function.

2016

Background Insulin resistance (IR), constitutes an important cardiovascular risk factor and can cause ischemic heart disease. It can lead to left ventricular dysfunction with a mechanism independent of ischemic heart disease and it is closely associated with impaired vascular function. The aim of our study was to explore the impact of IR on cardiac and vascular function, in patients with cardiovascular risk factors but angiographically undamaged coronary arteries. Methods We studied 32 patients (62.06 ± 11.19 years) with cardiovascular risk factors. All patients underwent coronary angiography, echocardiography, Doppler ultrasound of carotid arteries and laboratory tests. Exclusion criteria …

Malemedicine.medical_specialtyHomeostasis Model Assessment of Insulin Resistance (HOMA-IR)030209 endocrinology & metabolism030204 cardiovascular system & hematologyCoronary AngiographyRisk AssessmentCoronary artery disease03 medical and health sciences0302 clinical medicineInsulin resistanceVascular StiffnessRisk FactorsInternal medicinemedicineHumansPulse wave velocityAgedEjection fractionbusiness.industryvalvular heart diseaseAtrial fibrillationUltrasonography DopplerMiddle Agedmedicine.diseaseMyocardial dysfunctionCoronary arteriesCoronary artery disease (CAD)Arterial stiffnemedicine.anatomical_structureCarotid ArteriesItalyCardiovascular DiseasesEchocardiographyGlobal Longitudinal Strain (GLS)Arterial stiffnessCardiologyInsulin resistance (IR)FemaleInsulin ResistanceCardiology and Cardiovascular MedicinebusinessInternational journal of cardiology
researchProduct

Comparison between euglycemic hyperinsulinemic clamp and surrogate indices of insulin sensitivity in children with growth hormone deficiency

2018

Objective: Data about the impact of growth hormone treatment (GHT) on insulin sensitivity in children are quite controversial, due to the different surrogate indices that have been used. Design: We evaluated insulin sensitivity through the euglycemic hyperinsulinemic clamp, considered the gold standard technique, in 23 children affected by growth hormone deficiency (GHD) at baseline and after 12. months of GHT and in 12 controls with short stature at baseline, and we compared the clamp-derived index (M-value) with the most commonly used surrogate index of insulin sensitivity, as ISI Matsuda, and with circulating plasma markers of insulin sensitivity, as adiponectin and resistin levels. Resu…

Malemedicine.medical_specialtyHormone Replacement TherapyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismShort statureGrowth hormone deficiencySettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicineGlucose IntolerancemedicineHumansResistinProspective StudiesChildGrowth DisordersEuglycemic hyperinsulinemic clampAdiponectinHuman Growth Hormonebusiness.industryGrowth hormone deficiency; Hyperinsulinemic clamp; Insulin sensitivity; Endocrinology Diabetes and Metabolism; EndocrinologyInsulin sensitivityHyperinsulinemic clampGold standard (test)Glucose Tolerance TestPrognosismedicine.diseaseInsulin sensitivityGrowth hormone treatmentEndocrinologyCase-Control Studies030220 oncology & carcinogenesisGlucose Clamp TechniqueFemaleResistinGrowth hormone deficiencyAdiponectinInsulin Resistancemedicine.symptombusinessBiomarkersFollow-Up Studies
researchProduct

Imeglimin Normalizes Glucose Tolerance and Insulin Sensitivity and Improves Mitochondrial Function in Liver of a High-Fat, High-Sucrose Diet Mice Mod…

2015

International audience; Imeglimin is the first in a new class of oral glucose-lowering agents currently in phase 2b development. Although imeglimin improves insulin sensitivity in humans, the molecular mechanisms are unknown. This study used a model of 16-week high-fat, high-sucrose diet (HFHSD) mice to characterize its antidiabetic effects. Six-week imeglimin treatment significantly decreased glycemia, restored normal glucose tolerance, and improved insulin sensitivity without modifying organs, body weights, and food intake. This was associated with an increase in insulin-stimulated protein kinase B phosphorylation in the liver and muscle. In liver mitochondria, imeglimin redirects substra…

Malemedicine.medical_specialtyMale Animals Mice Inbred C57BL Insulin Resistance/*physiology Diet High-Fat/adverse effects Hypoglycemic Agents/*therapeutic use Liver/*drug effects/*metabolism Mitochondria/*drug effects/*metabolism Triazines/*therapeutic useImegliminMitochondria/*drug effects/*metabolismEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]High-Fat/adverse effectsBiologyMitochondrionDiet High-Fatmedicine.disease_causeInbred C57BLchemistry.chemical_compoundMiceLipid oxidationInternal medicineInternal MedicinemedicineHypoglycemic Agents/*therapeutic useHypoglycemic AgentsAnimalsProtein kinase BBeta oxidationComputingMilieux_MISCELLANEOUS2. Zero hungerchemistry.chemical_classificationReactive oxygen speciesTriazines/*therapeutic useTriazinesMitochondria3. Good healthDietMice Inbred C57BL[SDV] Life Sciences [q-bio]EndocrinologyLiver/*drug effects/*metabolismLiverchemistryInsulin Resistance/*physiologyCoenzyme Q – cytochrome c reductaseInsulin ResistanceOxidative stress
researchProduct